Orbia Fluor & Energy Materials (Orbia), has announced it has supplied its first large-scale delivery of its new low global warming potential (low-GWP) medical propellant, Zephex 152a.
Mitra Mosharraf, PhD, M.B.A., CSO, HTD Biosystems will do a talk on "Strategies for Manufacturing and Analysis of Lipid-Based Nanomedicines and Vaccines" at PharmSci 360, on 10th November.
Gerresheimer has announced that it will further expand its partnership with Portal Instruments to commercialise the Prime NEXUS reusable, connected autoinjector platform.
Auto-injectors and pens enable patients to self-administer medication safely. These modern application systems replace visits to the doctor and reduce the burden on the healthcare system.
Nemera relies on Mitutoyo measurement and inspection solutions to ensure its health-critical dispensers, inhalers and pens deliver the exact specified amount of active ingredient.
In this article, Jim Donovan, general manager for Pfizer CentreOne, explores the concept of “lightspeed” development under high-pressure situations, such as pandemics and drug shortages.
RenovoRx, a life sciences company developing innovative targeted oncology therapies and commercialising RenovoCath, a patented, FDA-cleared drug-delivery device, has announced the launch of the PanTheR Post-Marketing Registry Study (NCT06805461).
Cambridge Healthcare Innovations (CHI), has announced Quattrii, the first ever dry powder inhaler (DPI) engine that is capable of delivering large volumes of biologic and mRNA molecules in a single inhalation.
